INTRODUCTION: Interferon- a ( @entity4020 ), produced by immune cells, exhibits pleiotropic anti- viral activity. @entity14572 pranobex (PI), a synthetic derivative of a @entity17262 , shows direct anti- viral activity, and also acts indirectly, by activation of immune cells. The aim of this study was to evaluate an in vitro inhibition of Coxackievirus A16 (CAI6), enterovirus 71 (EV71) and @entity1 @entity15609 virus 4 (HPIV-4) replication by PI in combination with @entity4020 . MATERIALS AND METHODS: In the present study we evaluated an in vitro effect of interferon-a and @entity14572 pranobex on replication ofRNAviruses: CA-16, EV71, HPIV-4. Antiviral effects of @entity4020 and IPwere assessed by phenotypic assays. The yield reduction assay (YRA), which evaluates the ability of the compounds to inhibit virus multiplication in cell cultures, was ap- plied. The Reed-Muench statistical method was used to determine the 50% end point (IC51). RESULTS: Our studies have shown that combination of @entity4020 and @entity14572 pranobex dis- play higher efficacy than treatment with either compound alone, and suggest syn- ergy that may increase therapeutic effectiveness. The reduction of the average viral ti- ters of EV71, CA-16 and HPIV-4 in A549 cell culture after applying 400 Ig/ @entity19775 and @entity4020 (1000 IU/mL), in comparison to the viral titer in the control was reduced by 1,76 log,, TCID,,/ml, o 3,00 log, TCID50/ml , and 1,60 log,( TCID50/ml respec- tively. The antiviral activity of the tested compounds was also analyzed on the basis of IC., values. Application of 1000 IU/ml @entity4020 , with PI after infection of A549 cells with mention above viruses reduced the IC,, by 3,5%, 41,3% and 29% respectively. CONCLUSIONS: Our study demonstrated that enhanced antiviral activity was observed when cells infected with RNA viruses were treated with combination of @entity4020 and IP. The ef- fectiveness of @entity4020 and IP under these conditions has not been previously reported. CA16 virus turned out to be the most sensitive to the action of used inhibitors.

Interferon-a and XXXX pranobex-mediated inhibition of reploication of @entity1 RNA viruses in vitro.

@entity1 :: ('9606', 'Species') :: ['human'] @entity17262 :: ('D011687', 'Chemical') :: ['purine'] @entity19775 :: ('12608(Tax:10090)', 'Gene') :: ['mL Ip'] @entity14572 :: ('MESH:D007288', 'Chemical') :: ['Inosine', 'inosine'] @entity15609 :: ('MESH:D018184', 'Disease') :: ['parainfluenza'] @entity4020 :: ('3440', 'Gene') :: ['IFN-a']
@entity14572 :: (MESH:D007288,Chemical) :: ['inosine']
